Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
featured
DE-117 Spectrum 5 Study

Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost/non-responder subjects diagnosed with POAG or OHT &nbsp

intraocular pressure
ophthalmic solution
latanoprost
glaucoma
corrected visual acuity
  • 69 views
  • 23 Nov, 2020
  • 1 location
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

reduction after 4 weeks of treatment with DE-117 ophthalmic solution is non-inferior to latanoprost ophthalmic solution 0.005%.

intraocular pressure
hypertension
latanoprost ophthalmic solution
primary open angle glaucoma
brimonidine tartrate ophthalmic solution
  • 0 views
  • 08 Nov, 2020
  • 1 location
Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

, pseudoexfoliative glaucoma, or ocular hypertension. Researchers want to find out more about how 2 drugs called Cosopt (dorzolamide hydrochloride and timolol maleate) and Xalatan (latanoprost) can help

laser trabeculoplasty
ophthalmic solution
latanoprost
dorzolamide
timolol
  • 24 views
  • 07 Nov, 2020
  • 1 location
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

  • 0 views
  • 26 Nov, 2020
  • 1 location
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%) or to latanoprost 0.005%. Following the

intraocular pressure
ophthalmic solution
latanoprost
glaucoma
hypertension
  • 0 views
  • 01 Jul, 2020
  • 1 location
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma

The purpose of the study is to provide evidence that the efficacy of Xalatan will be superior to Apo-latanoprost and Co-latanoprost in the reduction of intraocular pressure in patients with

intraocular pressure
xalatan
treatment of glaucoma
travoprost
primary open angle glaucoma
  • 0 views
  • 08 Nov, 2020
  • 1 location
Open Label Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who have Primary Open Angle Glaucoma.

latanoprost
retinopathy
corrected visual acuity
diabetic retinopathy
primary open angle glaucoma
  • 0 views
  • 04 Nov, 2020
  • 10 locations
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments. Current trial-and-error approaches to glaucoma management are inefficient and have not addressed this barrier as there are no predictive …

intraocular pressure
blindness
gonioscopy
latanoprost 0.005% eye drops
visual field tests
  • 0 views
  • 17 Sep, 2020
  • 3 locations
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective. However, adherence to eye drop treatment is poor with only 50% of patients regularly taking their prescribed …

blindness
ophthalmic solution
latanoprost
  • 0 views
  • 15 Oct, 2020
  • 1 location
Topical Cetirizine in Androgenetic Alopecia in Females

Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist, widely used in daily practice. A study showed that cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical cetirizine showed that cetirizine increased total hair density, terminal hair density …

combinations
histamine h1 receptor antagonist
alopecia
prostaglandins
androgenic alopecia
  • 437 views
  • 30 Jul, 2020
  • 1 location